Literature DB >> 8744974

Role of tachykinins as excitatory mediators of NANC contraction in the circular muscle of rat small intestine.

C A Maggi1, S Giuliani.   

Abstract

1. The aim of this study was to assess the role of tachykinins, acting via NK1 and NK2 receptors, in mediating nonadrenergic noncholinergic (NANC) contractions produced by electrical field stimulation (EFS) in the circular muscle of the rat small intestine. 2. In the presence of atropine (1 microM), guanethidine (3 microM), indomethacin (10 microM), apamin (0.3 microM) and L-nitroarginine (L-NOARG, 100 microM) and after in vitro capsaicin (10 microM for 15 min) pretreatment, EFS (0.25 ms pulse width, 100 V, 1-30 Hz for 5 s) produced a frequency-dependent NANC contraction of mucosa-free circular muscle strips from the rat proximal duodenum and terminal ileum. In the duodenum, the NANC contraction was preceded by a transient NANC relaxation. All responses to EFS were abolished by 1 microM tetrodotoxin. 3. The NK1 receptor selective antagonist, SR 140,333 (0.1 microM for 60 min) and the NK2 receptor selective antagonist, MEN 10,627 (0.1 microM for 60 min), both produced a partial inhibition of the contractile response to EFS. The co-administration of SR 140,333 and MEN 10,627 produced a profound inhibition of the response to EFS in the duodenum, larger than that produced by each antagonist alone; a fraction (about 25% of the response at 30 Hz) of the NANC contraction of the duodenum persisted in the presence of the two antagonists. This residual response was however abolished after co-administration of the NK1 and NK2 receptor antagonists, GR 94,800 (1 microM) and GR 82,334 (10 microM). The co-administration of SR 140,333 and MEN 10,627 nearly abolished the NANC contraction to EFS in the ileum. 4. Nifedipine (1 microM) induced a profound depression of the NANC contraction to EFS in both duodenal and ileal strips. A fraction of the response to EFS (about 25 and 5-10% of the response at 30 Hz in the duodenum and ileum, respectively) was nifedipine-resistant. SR 140,333 (0.1 microM) had little effect on the nifedipine-resistant response to EFS in the duodenum although it reduced by about 50% the response in the ileum. MEN 10,627 (0.1 microM) produced a partial inhibitory effect of the nifedipine-resistant response in both regions. The co-administration of SR 140,333 and MEN 10,627 nearly abolished the nifedipine-resistant response in the ileum while a small fraction (about 20% of control) of the response persisted in the duodenum.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8744974     DOI: 10.1111/j.1474-8673.1995.tb00400.x

Source DB:  PubMed          Journal:  J Auton Pharmacol        ISSN: 0144-1795


  5 in total

1.  Role of cyclooxygenases 1 and 2 in the modulation of neuromuscular functions in the distal colon of humans and mice.

Authors:  M Fornai; C Blandizzi; R Colucci; L Antonioli; N Bernardini; C Segnani; B Baragatti; S Barogi; P Berti; R Spisni; M Del Tacca
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

2.  Evidence that tachykinin NK2 receptors modulate resting tone in the rat isolated small intestine.

Authors:  C A Maggi; S Giuliani
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

3.  Altered prejunctional modulation of intestinal cholinergic and noradrenergic pathways by alpha2-adrenoceptors in the presence of experimental colitis.

Authors:  Corrado Blandizzi; Matteo Fornai; Rocchina Colucci; Fabio Baschiera; Giovanni Barbara; Roberto De Giorgio; Fabrizio De Ponti; Maria Cristina Breschi; Mario Del Tacca
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

4.  Alteration of neuromuscular transmissions in the hamster colon following the resolution of TNBS-induced colitis.

Authors:  Takahiko Shiina; Yam B Gurung; Yuji Suzuki; Tadashi Takewaki; Yasutake Shimizu
Journal:  J Physiol Sci       Date:  2013-04-09       Impact factor: 2.781

Review 5.  Neurogenic inflammation after traumatic brain injury and its potentiation of classical inflammation.

Authors:  Frances Corrigan; Kimberley A Mander; Anna V Leonard; Robert Vink
Journal:  J Neuroinflammation       Date:  2016-10-11       Impact factor: 8.322

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.